We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Highlights of Vol 4 | Issue 8 | 2026
The present study aimed to formulate and evaluate a Gastroretentive mucoadhesive In-situ gel of Pioglitazone Hydrochloride using the ion-activated gelation method for the...
This study evaluated the antifungal effects of Miconazole Nitrate combined with Carica papaya seed oil and Nigella seed oil in microemulsion form, and investigated potent...
Narcotics and psychotropic substances (NDPS) are essential for medical treatment but carry high risks of addiction and potential for abuse, necessitating strict internati...
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. The in...
Obesity is a global chronic disease affecting over 1 billion adults, conferring significant morbidity and mortality through associated cardiometabolic comorbidities. Phar...
Background: Coronary Artery Disease continues to place a substantial burden on healthcare systems, yet the way it develops and presents can differ between men and women. ...
Its natural conduct is vulnerable modulation, repression of platelet aggregation and support of tissue rejuvenescence. Those mechanisms define bromelain as an important n...
Nigeria’s heavy reliance on imported vaccines and medicines exposes weaknesses in governance, strategic planning, and manufacturing capacity, increasing the vulnerabili...
Artificial intelligence (AI) and machine learning (ML) are now embedded in hundreds of regulated medical products, yet the frameworks that govern their post-market safety...
Background Bexarotene is a potent anticancer drug used in the treatment of cutaneous T-cell lymphoma; however, its clinical application is limited by poor aqueous solubil...
Hemophilia, which means “love” (philia) of blood (hem), is the most common severe hereditary hemorrhagic disease. Hemophilia A and B are congenital bleeding disorders...
Fenofibrate is a Biopharmaceutical Classification System (BCS) Class II drug with poor aqueous solubility and limited oral bioavailability, which may reduce its therapeut...